salicylamide has been researched along with catechol in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Aué, GH; Bultsma, T; IJzerman, AP; Linschoten, MR; Timmerman, H | 1 |
Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
Cohen, SM; Fullagar, JL; Jacobsen, JA; Miller, MT | 1 |
Cardey, B; Desingle, C; Foley, S; Girard, C; Grzybowski, M; Harakat, D; Muller, J; Pomper, P; Pudlo, M; Ramseyer, C; Zedet, A | 1 |
4 other study(ies) available for salicylamide and catechol
Article | Year |
---|---|
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
Topics: Animals; Cattle; Chemical Phenomena; Chemistry; Dihydroalprenolol; Ethanolamines; Guanylyl Imidodiphosphate; Hydrogen-Ion Concentration; Muscles; Propanolamines; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1985 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
Topics: Antigens, Bacterial; Bacterial Toxins; Chelating Agents; Copper; Drug Design; Humans; Hydroxyquinolines; Iron; Ligands; Lipoxygenase Inhibitors; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Monophenol Monooxygenase; Nitric Oxide Synthase Type II; Recombinant Proteins; Small Molecule Libraries; Structure-Activity Relationship; Sulfonamides; Zinc | 2011 |
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.
Topics: | 2020 |